Kumquat Biosciences

SAN DIEGO, CA · Founded 2018 · Biotech · Private

Cancer immunotherapies and cell-based therapeutics

Claim this profile

Follows are private to you and power your alerts

Updated · kumquatbiosciences.com

Sector
Biotech
Headquarters
SAN DIEGO, CA
Founded
2018
Latest Form D
$20M, Aug 2021
Total capital
$117M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$117M
3 Form D · last Aug 2021
63 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
11
29 pending · first 2023
Rank in peer group#3 of 55

Capital timeline

201920202021FEDERAL ↑EQUITY ↓Cumulative $117M1st Form D$47M2nd Form D$50M3rd Form D$20M
201920202021FEDERAL ↑EQUITY ↓Cumulative $117M1st Form D$47M2nd Form D$50M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$20M
  • Private capital raisedForm D · SEC · 2nd filing$50M
  • Private capital raisedForm D · SEC · 1st filing$47M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 55 peers

Line = median

Biotech · Software

  • Granted patents#3 · top 5%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Pingda RenResearcherExecutive OfficerLinked by 1 patent
  • Carl GordonDirectorNamed in SEC Form D filings
  • Lynn YangDirectorNamed in SEC Form D filings
  • Scott PlatshonDirectorNamed in SEC Form D filings
  • Yi LiuExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 11 granted of 40
  • PendingRas InhibitorsUSPTOApplication 19564596
  • PendingSUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AND QUINAZOLINES AS INHIBITORS OF RAS PATHWAY SIGNALINGUSPTOApplication 19644459
  • PendingCovalent Heterocycles And Uses ThereofUSPTOApplication 19306039
Show all 40 patent records
  • Ras InhibitorsSep 17, 2026 · Application 19564596Pending
  • SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AND QUINAZOLINES AS INHIBITORS OF RAS PATHWAY SIGNALINGJul 30, 2026 · Application 19644459Pending
  • Covalent Heterocycles And Uses ThereofJul 30, 2026 · Application 19306039Pending
  • Substituted Heteroaromatic Amines And Uses ThereofJun 30, 2026 · US 12,668,600Granted
  • Macrocyclic Heterocycles And Uses ThereofMay 14, 2026 · Application 19259309Pending
  • Heterocyclic Compounds And Uses ThereofApr 23, 2026 · Application 19337361Pending
  • Substituted Heterocycles And Uses ThereofApr 21, 2026 · US 12,606,572Granted
  • Compositions And Methods For Potentiating Immune ActivityFeb 17, 2026 · US 12,551,555Granted
  • 1,2,5-thiadiazolidin-3-one 1,1-dioxide containing compounds and uses thereofDec 23, 2025 · US 12,503,464Granted
  • Heterocycles And Uses ThereofDec 18, 2025 · Application 19243961Pending
  • Benzo-fused N-heterocycles And Uses ThereofOct 2, 2025 · Application 19075486Pending
  • Heterocyclic Compounds And Uses ThereofJul 22, 2025 · US 12,365,676Granted
  • Heterocyclic Compounds And Uses ThereofApr 29, 2025 · US 12,286,427Granted
  • Heterocyclic Compounds And Uses ThereofJan 28, 2025 · US 12,209,102Granted
  • Macrocyclic Heterocycles And Uses ThereofJan 14, 2025 · US 12,195,465Granted
  • Heterocyclic Compounds And Uses ThereofDec 26, 2024 · Application 18787939Pending
  • Hetero-atom Containing Compounds And Uses ThereofDec 5, 2024 · Application 18669349Pending
  • Heterocyclic Compounds And Uses ThereofNov 28, 2024 · Application 18634495Pending
  • Heterocyclic Compounds And Uses ThereofNov 7, 2024 · Application 18506478Pending
  • Covalent Heterocycles And Uses ThereofSep 5, 2024 · Application 18394183Pending
  • Macrocyclic Heterocycles And Uses ThereofAug 15, 2024 · Application 18521254Pending
  • Heterocyclic Compounds And Uses ThereofAug 13, 2024 · US 12,059,425Granted
  • Heterocyclic Compounds And Uses ThereofAug 1, 2024 · Application 18446017Pending
  • Heterocycles And Uses ThereofMay 23, 2024 · Application 18463134Pending
  • Heterocyclic Compounds And Uses ThereofApr 11, 2024 · Application 18311850Pending
  • Heterocyclic Compounds And Uses ThereofApr 4, 2024 · Application 18311853Pending
  • Modulators Of Cell Proliferation And Uses ThereofMar 14, 2024 · Application 18297211Pending
  • Macrocyclic Heterocycles And Uses ThereofFeb 27, 2024 · US 11,912,708Granted
  • SUBSTITUTED PYRIDO[2,3-d]PYRIMIDINES AS INHIBITORS OF RAS PATHWAY SIGNALINGMay 16, 2023 · US 11,648,254Granted
  • Compositions And Methods For Potentiating Immune ResponseMar 23, 2023 · Application 17838068Pending
  • Compositions And Methods For Targeting Cellular MoleculesJan 5, 2023 · Application 17636692Pending
  • Heterocyclic Conjugates And Uses ThereofApplication 63700538Pending
  • Methods Of Modulating Cell ProliferationApplication PCTUS2024052874Pending
  • Heterocyclic Compounds And Uses ThereofApplication 63724227Pending
  • Covalent Heterocycles And Uses ThereofApplication 19009057Pending
  • Heterocyclic Compounds And Uses ThereofApplication 63724230Pending
  • Methods Of Modulating Cell ProliferationApplication PCTUS2024052878Pending
  • Methods Of Modulating Cell ProliferationApplication PCTUS2024052876Pending
  • Heterocyclic Conjugates And Uses ThereofApplication PCTUS2025014660Pending
  • Heterocyclic Compounds And Uses ThereofApplication PCTUS2025056430Pending
  • UroGen Pharma Ltd.Similar federal contract value in Biotech · null in contracts
  • ANAGINSimilar federal contract value in Biotech · null in contracts
  • Scipher Medicine CorpSimilar federal contract value in Biotech · null in contracts
  • JME Group Associates IncSimilar federal contract value in Biotech · null in contracts
  • OTHRAM, INC.Similar federal contract value in Biotech · null in contracts
  • Synnovation TherapeuticsSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .